## Hsa-miR-142-3p miRNA Probe (DIG)

Catalog \# MIOOO6 Size 100 uL

## Applications



## Chromogenic In Situ Hybridization (FFPE Tissue)

(A) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing positive staining on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues.
(B) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing negative staining on FFPE human pancreas tissue and the negative controls on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues in the absence of probe (No Probe) followed by incubation with primary antibody, secondary antibody and detection reagents.

## Specification

## Product Description

Hsa-miR-142-3p miRNA Probe (DIG) designed from mature human miR-142 sequence.

| miRbase ID | MIMAT0000434 |
| :--- | :--- |
| Origin | Human |
| Reactivity | Human |
| Form | Liquid |
| Conjugation | Use of FFPE miRNA ISH Pretreatment Solution for the pretreatment of formalin-fixed paraffin-embed <br> ded (FFPE) tissue sections is strongly recommended. |
| Notice | For research use only (RUO) |
| Regulation Status | 10 reactions, 100 uL miRNA probe |
| Supplied Product |  |

Product Information

Storage Instruction Store at $4^{\circ} \mathrm{C}$.

## Applications

- Chromogenic In Situ Hybridization (FFPE Tissue)
(A) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing positive staining on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues.
(B) microRNA in situ hybridization analysis of Hsa-miR-142-3p miRNA Probe (DIG) showing negative staining on FFPE human pancreas tissue and the negative controls on FFPE human breast cancer, placenta, colon, lymph node, colon cancer and ovarian cancer tissues in the absence of probe (No Probe) followed by incubation with primary antibody, secondary antibody and detection reagents.

